クリングルファーマ株式会社.

NEWS

お知らせ


Warning: Invalid argument supplied for foreach() in /home/r3716923/public_html/kringle-pharma.com/wp-content/themes/kringle_pharma/view/single/default.php on line 21
2018.05.11

Acute SCI Phase I/II LPO

Kringle Pharma announces that the last subject has completed the follow-up period after dosing in the Phase I/II study of recombinant human HGF for acute spinal cord injury.